Lung Cancer

Frontline iza-bren in combination with serplulimab was associated with a tolerable and manageable safety profile and elicited responses in ES-SCLC.

Osimertinib plus chemotherapy prolonged PFS vs osimertinib alone in patients with advanced NSCLC harboring concurrent EGFR and TP53 mutations.

Read on to see what abstracts experts in the field of lung cancer are interested in learning more about at ELCC 2026 in Copenhagen, Denmark.

PFS was improved when patients with advanced EGFR exon 20 insertion–positive NSCLC received sunvozertinib vs platinum chemotherapy in the first line.

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

CNS-penetrant TKIs are reshaping brain metastases care in lung cancer, shifting sequencing decisions between systemic and local therapy.

A drug withdrawal in follicular lymphoma and epithelioid sarcoma, a CRL in lung cancer, and priority review in breast cancer highlight this week's top oncology news.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The phase 3 TACTI-004 trial in patients with NSCLC has been discontinued in accordance with an independent data monitoring committee recommendation.

Researchers at Dana-Farber Cancer Institute show why SCLC stays out of reach of the immune system, even when cancer cells are vulnerable to immune attack.

PD-L1 expression may signal worse outcomes with frontline osimertinib in EGFR-mutant metastatic NSCLC, highlighting potential prognostic value.

The FDA has issued a CRL for retifanlimab plus chemotherapy in metastatic NSCLC citing compliance issues at a third-party facility.

Continuing treatment with zenocutuzumab beyond disease progression was effective and safe in patients with advanced NRG1+ NSCLC.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

Eric K. Singhi, MD, discusses where TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan may fit in evolving treatment algorithms in lung cancer.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

The FDA has granted accelerated approval to zongertinib in HER2 TKD–mutated NSCLC, full approval to an encorafenib combination in BRAF V600E+ mCRC, and more.

Anne Chiang, MD, PhD, discusses the rapidly evolving treatment landscape in SCLC and what this new era of innovation means for patients.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

David Carbone, MD, PhD, discusses the 6-year data from the phase 3 CheckMate 9LA trial (NCT03215706).

Balazs Halmos, MD, MS, highlights the significance of the accelerated approval of zongertinib in HER2 TKD–mutated non–small cell lung cancer.

The FDA expanded the indication for zongertinib in unresectble or metastatic nonsquamous NSCLC harboring HER2 TKD mutations.

The FDA approved a frontline acalabrutinib regimen in CLL/SLL and a simplified dosing schedule for Rybrevant Faspro in EGFR+ NSCLC and will review NDAs in PCNSL and breast cancer.

Alexander I. Spira, MD, PhD, FACP, FASCO, discusses the FDA approval of subcutaneous amivantamab for patients with EGFR-mutated NSCLC.